Myths About iPSCs: Top Misconceptions Debunked by Science

Blogs

Induced pluripotent stem cells (iPSCs) are among the most transformative innovations in modern regenerative medicine. The concept itself seems almost futuristic: by taking a small sample of somatic cells, such as skin fibroblasts, and reprogramming them back into a pluripotent state. These reprogrammed cells can give rise to diverse cell types, opening new possibilities for personalized medicine, disease modelling, and tissue regeneration.

Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation

Blogs

Classic epigenetic modifications include DNA methylation and histone modifications as well as more broadly chromatin accessibility and non-coding RNAs. Epigenetic mechanisms enable heritable changes in gene expression that occur without altering the underlying DNA sequence. The various epigenetic layers act to control DNA accessibility and chromatin structure, which defines transcription factor binding and downstream gene…

Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed

Blogs

1. Ethical and Regulatory Compliance The challenge: Clinical and commercial applications require strict ethical oversight and compliance with global regulatory standards. Our solution: REPROCELL follows IRB-approved informed consent protocols, and the clinical iPSC generation is compliant with all major regulatory standards (FDA, EMA, PMDA). We ensure: Full donor de-identification Ethical donor recruitment Global consent for clinical and…

REPROCELL and Histocell have achieved GMP certification for their manufacturing process of clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs, ensuring high-quality and safe production for regenerative medicine applications.

Corporate News

Yokohama, Japan / Bilbao, Spain – October 20th — REPROCELL (Yokohama, Japan; TYO: 4978) and Histocell (Bilbao, Spain) are proud to announce that the Spanish Agency for Medicines and Medical Devices (AEMPS), operating under European Medicines Agency (EMA) oversight, has granted to Histocell Good Manufacturing Practice (GMP) certificate and authorization of the manufacturing process of induced Pluripotent…

Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?

Blogs

The Power of mRNA Reprogramming The emergence of mRNA reprogramming offers a precise, efficient, and xeno-free approach to generating induced pluripotent stem cells (iPSCs). These versatile cells hold immense potential for personalized medicine, disease modelling, and drug discovery. REPROCELL has led the way in mRNA reprogramming, in 2010 becoming the first company to commercialize mRNA-based…

Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy

Blogs

Induced Pluripotent Stem Cells (iPSCs) are revolutionizing regenerative medicine. They play a pivotal role in disease modeling and modern cell therapy development. One of the challenges with cell-based models is scale: How do we get sufficient cells at an affordable cost? Suspension cultures using bioreactors offer a solution.Bioreactors are available from several vendors in scales…

REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy

Corporate News

Yokohama, Japan, August 20, 2025 REPROCELL is proud to announce the introduction of NeoSight – Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications. This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal…

REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model

Corporate News

Glasgow, UK — Scientists from REPROCELL Europe, working in collaboration with researchers at Durham University, have successfully developed a full-thickness human skin model using fibroblasts derived from induced pluripotent stem cells (iPSCs). The breakthrough, published in Cells (14(14):1044, 2025), demonstrates a novel approach to producing consistent, high-quality human skin constructs for research and therapeutic applications. Current skin models…

Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

Corporate News

YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…